These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 36140394)

  • 41. Tryptophan-2,3-dioxygenase (TDO) inhibition ameliorates neurodegeneration by modulation of kynurenine pathway metabolites.
    Breda C; Sathyasaikumar KV; Sograte Idrissi S; Notarangelo FM; Estranero JG; Moore GG; Green EW; Kyriacou CP; Schwarcz R; Giorgini F
    Proc Natl Acad Sci U S A; 2016 May; 113(19):5435-40. PubMed ID: 27114543
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A novel causative role of imbalanced kynurenine pathway in ulcerative colitis: Upregulation of KMO and KYNU promotes intestinal inflammation.
    Shi Y; Luo S; Zhai J; Chen Y
    Biochim Biophys Acta Mol Basis Dis; 2024 Feb; 1870(2):166929. PubMed ID: 37918679
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A series of N-terminal epitope tagged Hdh knock-in alleles expressing normal and mutant huntingtin: their application to understanding the effect of increasing the length of normal Huntingtin's polyglutamine stretch on CAG140 mouse model pathogenesis.
    Zheng S; Ghitani N; Blackburn JS; Liu JP; Zeitlin SO
    Mol Brain; 2012 Aug; 5():28. PubMed ID: 22892315
    [TBL] [Abstract][Full Text] [Related]  

  • 44. On the relationship between the two branches of the kynurenine pathway in the rat brain in vivo.
    Amori L; Guidetti P; Pellicciari R; Kajii Y; Schwarcz R
    J Neurochem; 2009 Apr; 109(2):316-25. PubMed ID: 19226371
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Maternal genotype determines kynurenic acid levels in the fetal brain: Implications for the pathophysiology of schizophrenia.
    Beggiato S; Notarangelo FM; Sathyasaikumar KV; Giorgini F; Schwarcz R
    J Psychopharmacol; 2018 Nov; 32(11):1223-1232. PubMed ID: 30354938
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Huntingtin and Its Partner Huntingtin-Associated Protein 40: Structural and Functional Considerations in Health and Disease.
    Seefelder M; Klein FAC; Landwehrmeyer B; Fernández-Busnadiego R; Kochanek S
    J Huntingtons Dis; 2022; 11(3):227-242. PubMed ID: 35871360
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Kynurenine pathway metabolic balance influences microglia activity: Targeting kynurenine monooxygenase to dampen neuroinflammation.
    Garrison AM; Parrott JM; Tuñon A; Delgado J; Redus L; O'Connor JC
    Psychoneuroendocrinology; 2018 Aug; 94():1-10. PubMed ID: 29734055
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Mutant huntingtin's interaction with mitochondrial protein Drp1 impairs mitochondrial biogenesis and causes defective axonal transport and synaptic degeneration in Huntington's disease.
    Shirendeb UP; Calkins MJ; Manczak M; Anekonda V; Dufour B; McBride JL; Mao P; Reddy PH
    Hum Mol Genet; 2012 Jan; 21(2):406-20. PubMed ID: 21997870
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Kynurenine 3-monooxygenase deficiency induces depression-like behavior via enhanced antagonism of α7 nicotinic acetylcholine receptors by kynurenic acid.
    Mori Y; Mouri A; Kunisawa K; Hirakawa M; Kubota H; Kosuge A; Niijima M; Hasegawa M; Kurahashi H; Murakami R; Hoshi M; Nakano T; Fujigaki S; Fujigaki H; Yamamoto Y; Nabeshima T; Saito K
    Behav Brain Res; 2021 May; 405():113191. PubMed ID: 33607168
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The causative role and therapeutic potential of the kynurenine pathway in neurodegenerative disease.
    Amaral M; Outeiro TF; Scrutton NS; Giorgini F
    J Mol Med (Berl); 2013 Jun; 91(6):705-13. PubMed ID: 23636512
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The Gln-Ala repeat transcriptional activator CA150 interacts with huntingtin: neuropathologic and genetic evidence for a role in Huntington's disease pathogenesis.
    Holbert S; Denghien I; Kiechle T; Rosenblatt A; Wellington C; Hayden MR; Margolis RL; Ross CA; Dausset J; Ferrante RJ; Néri C
    Proc Natl Acad Sci U S A; 2001 Feb; 98(4):1811-6. PubMed ID: 11172033
    [TBL] [Abstract][Full Text] [Related]  

  • 52. N-(6-phenylpyridazin-3-yl)benzenesulfonamides as highly potent, brain-permeable, and orally active kynurenine monooxygenase inhibitors.
    Kimura H; Suda H; Kassai M; Endo M; Deai Y; Yahata M; Miyajima M; Isobe Y
    Bioorg Med Chem Lett; 2021 Feb; 33():127753. PubMed ID: 33359168
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Development of a Rapid Fluorescence-Based High-Throughput Screening Assay to Identify Novel Kynurenine 3-Monooxygenase Inhibitor Scaffolds.
    Jacobs KR; Guillemin GJ; Lovejoy DB
    SLAS Discov; 2018 Jul; 23(6):554-560. PubMed ID: 29420107
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Aberrant splicing of mutant huntingtin in Huntington's disease knock-in pigs.
    Tong H; Yang T; Liu L; Li C; Sun Y; Jia Q; Qin Y; Chen L; Zhao X; Zhou G; Yan S; Li XJ; Li S
    Neurobiol Dis; 2023 Oct; 187():106291. PubMed ID: 37716514
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Mutant huntingtin promotes the fibrillogenesis of wild-type huntingtin: a potential mechanism for loss of huntingtin function in Huntington's disease.
    Busch A; Engemann S; Lurz R; Okazawa H; Lehrach H; Wanker EE
    J Biol Chem; 2003 Oct; 278(42):41452-61. PubMed ID: 12888569
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Rapamycin reduces neuronal mutant huntingtin aggregation and ameliorates locomotor performance in
    Roth JR; de Moraes RCM; Xu BP; Crawley SR; Khan MA; Melkani GC
    Front Aging Neurosci; 2023; 15():1223911. PubMed ID: 37823007
    [TBL] [Abstract][Full Text] [Related]  

  • 57. First molecular modeling report on novel arylpyrimidine kynurenine monooxygenase inhibitors through multi-QSAR analysis against Huntington's disease: A proposal to chemists!
    Amin SA; Adhikari N; Jha T; Gayen S
    Bioorg Med Chem Lett; 2016 Dec; 26(23):5712-5718. PubMed ID: 27838184
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Deterioration of neuroregenerative plasticity in association with testicular atrophy and dysregulation of the hypothalamic-pituitary-gonadal (HPG) axis in Huntington's disease: A putative role of the huntingtin gene in steroidogenesis.
    Selvaraj K; Manickam N; Kumaran E; Thangadurai K; Elumalai G; Sekar A; Radhakrishnan RK; Kandasamy M
    J Steroid Biochem Mol Biol; 2020 Mar; 197():105526. PubMed ID: 31715317
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Alternative processing of human HTT mRNA with implications for Huntington's disease therapeutics.
    Fienko S; Landles C; Sathasivam K; McAteer SJ; Milton RE; Osborne GF; Smith EJ; Jones ST; Bondulich MK; Danby ECE; Phillips J; Taxy BA; Kordasiewicz HB; Bates GP
    Brain; 2022 Dec; 145(12):4409-4424. PubMed ID: 35793238
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Towards a comprehensive understanding of the contributions of mitochondrial dysfunction and oxidative stress in the pathogenesis and pathophysiology of Huntington's disease.
    Tobore TO
    J Neurosci Res; 2019 Nov; 97(11):1455-1468. PubMed ID: 31304621
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.